Asset Details
Do you wish to reserve the book?
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
Do you wish to request the book?
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
2010
Overview
Cognitive impairment in patients with Parkinson's disease is gaining increased clinical significance owing to the relative success of therapeutic approaches to the motor symptoms of this disorder. Early investigations contributed to the concept of subcortical dementia associated with bradyphrenia and cognitive rigidity. For cognition in parkinsonian disorders, this notion developed into the concept of mild cognitive impairment and fronto-executive dysfunction in particular, driven mainly by dopaminergic dysmodulation and manifesting as deficits in flexibility, planning, working memory, and reinforcement learning. However, patients with Parkinson's disease could also develop a syndrome of dementia that might depend on non-dopaminergic, cholinergic cortical dysfunction. Recent findings, supplemented by advances in neuroimaging and genetic research, reveal substantial heterogeneity in the range of cognitive deficits in patients with Parkinson's disease. Remediation and management prospects for these cognitive deficits are based on neuropharmacological and cognitive rehabilitation approaches.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
Cholinergic Agents - therapeutic use
/ Cognition Disorders - etiology
/ Cognition Disorders - genetics
/ Cognition Disorders - therapy
/ Cognitive Behavioral Therapy - methods
/ Dementia
/ Dopamine Agents - therapeutic use
/ Genetic Predisposition to Disease
/ Humans
/ Parkinson Disease - complications
